The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase

British Journal of Clinical Pharmacology

Volumn 72, Issue 5, 2011, Pages 775-786

  Vachharajani, Nimish N ^a,b   Raymond, Ralph H ^a   Shyu, Wen Chyi ^a,c   Stouffer, Bruce C ^a   Boulton, David W ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^b Advinus Therapeutics Private Limited Bangalore   (India)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Acute myocardial infarction; Age and gender effects on pharmacodynamics; Age and gender effects on pharmacokinetics; Fibrinolytic therapy; Plasminogen activation

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRINOGEN; LANOTEPLASE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 80053910062     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04003.x     Document Type: Article

References (25)

1. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 1996; 93: 857-65.
2. Cannon CP. Advances in the medical management of acute coronary syndromes. J Thromb Thrombolysis 1999; 7: 171-89.
3. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasinell'Infarto Miocardico (GISSI). Lancet 1986; 1: 397-402.
4. McGrath KG, Zeffren B, Alexander J, Kaplan K, Patterson R. Allergic reactions to streptokinase consistent with anaphylactic or antigen-antibody complex-mediated damage. J Allergy Clin Immunol 1985; 76: 453-7.
5. Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999; 81: 605-12.
6. Pierard L, Bollen A. Development of new thrombolytic agents using recombinant DNA technology. J Biotechnol 1990; 15: 283-304.
7. Product Label Information: Activase® (Alteplase, Recombinant Human Tissue-Type Plasminogen Activator). South San Francisco, CA: Genentech, Inc., 1999.
8. den Heijer P, Vermeer F, Ambrosioni E, Sadowski Z, Lopez-Sendon JL, von Essen R, Beaufils P, Thadani U, Adgey J, Pierard L, Brinker J, Davies RF, Smalling RW, Wallentin L, Caspi A, Pangerl A, Trickett L, Hauck C, Henry D, Chew P. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998; 98: 2117-25.
9. Nordt TK, Moser M, Kohler B, Kubler W, Bode C. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost 1999; 82 (Suppl. 1): 121-3.
10. Stegnar M, Pentek M. Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin. Thromb Res 1993; 69: 81-92.
11. Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull 1983; 64: 2-9.
12. Kostis JB, Dockens RC, Thadani U, Bethala V, Pepine C, Leimbach W, Vachharajani N, Raymond RH, Stouffer BC, Tay LK, Shyu WC, Liao WC. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin Pharmacokinet 2002; 41: 445-52.
13. Stouffer B, Habte S, Vachharajani N, Tay L. Validation of an ELISA for the quantitation of lanoteplase, a novel plasminogen activator. J Immunoassay 1999; 20: 237-52.
14. Ranby M, Norrman B, Wallen P. A sensitive assay for tissue plasminogen activator. Thromb Res Suppl 1982; 27: 743-9.
15. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, Inc., 1982; 409-17.
16. Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Applications, 2nd edn. Philadelphia, PA: Lea & Febiger, 1989.
17. Akaike H. An information criterion. Math Sci 1976; 14: 5-9.
18. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-5.
19. Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su CA, Kluft C. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung 1988; 38: 418-22.
20. Seifried E, Tanswell P, Ellbruck D, Haerer W, Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost 1989; 61: 497-501.
21. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998; 79: 134-9.
22. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, Palacios I, Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347-52.
23. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976; 251: 5956-65.
24. Wallen P. Biochemistry of plasminogen. In: Fibrinolysis, eds Kline DL, Reddy KNN. Boca Raton, FL: CRC Press, Inc, 1980; 1-24.
25. Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74.